Article
Gastroenterology & Hepatology
Rozanne C. de Veer, Maria C. van Hooff, Christophe Corpechot, Douglas Thorburn, Pietro Invernizzi, Willem J. Lammers, Harry L. A. Janssen, Pier M. Battezzati, Frederik Nevens, Keith D. Lindor, Annarosa Floreani, Cyriel Y. Ponsioen, Marlyn J. Mayo, Albert Pares, Andrew L. Mason, Kris V. Kowdley, Palak J. Trivedi, Gideon M. Hirschfield, Jorn C. Goet, Tony Bruns, George N. Dalekos, Nikolaos K. Gatselis, Xavier Verhelst, Bettina E. Hansen, Maren H. Harms, Adriaan J. van der Meer, Global PBC Study Grp
Summary: A study found an association between changes in the GLOBE score in patients with primary biliary cholangitis (PBC) treated with ursodeoxycholic acid (UDCA) and LT-free survival. The study assessed the risk of LT or death in UDCA-treated PBC patients based on changes in the GLOBE score.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Chung-Heng Liu, Christopher L. Bowlus
Summary: All patients with PBC should be treated with UDCA first and if there is an incomplete response, second-line therapies like OCA or bezafibrate should be considered. The use of OCA or fibrates in advanced or decompensated cirrhosis should be avoided, and for patients intolerant of UDCA, second-line agents may be used.
CLINICS IN LIVER DISEASE
(2022)
Article
Gastroenterology & Hepatology
Nadir Abbas, Emma L. Culver, Douglas Thorburn, Neil Halliday, Hannah Crothers, Jessica K. Dyson, April Phaw, Richard Aspinall, Salim I. Khakoo, Yiannis Kallis, Belinda Smith, Imran Patanwala, Anne McCune, Chenchu R. Chimakurthi, Vinod Hegade, Michael Orrell, Rebecca Jones, George Mells, Colette Thain, Robert-Mitchell Thain, David Jones, Gideon Hirschfield, Palak J. Trivedi
Summary: This study aimed to evaluate the effectiveness of obeticholic acid (OCA) and fibric acid derivatives as second-line treatments for primary biliary cholangitis. The study found that rates of biochemical response and drug discontinuation were similar between fibric acid derivatives and OCA in patients in the United Kingdom.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Review
Gastroenterology & Hepatology
Jakub Gazda, Sylvia Drazilova, Matej Gazda, Martin Janicko, Tomas Koky, Marian Macej, Marco Carbone, Peter Jarcuska
Summary: This study systematically reviewed and meta-analyzed various UDCA treatment response endpoints and their validations, finding that the GLOBE and UK-PBC Risk Scores serve as the most accurate predictive models. Additionally, the normalization of alkaline phosphatase and total bilirubin has been suggested as a new therapeutic target.
DIGESTIVE AND LIVER DISEASE
(2023)
Article
Gastroenterology & Hepatology
Cynthia Levy, Michael Manns, Gideon Hirschfield
Summary: Primary biliary cholangitis is an autoimmune disease with symptoms including fatigue, itch, abdominal pain, and sicca complex. Treatment focuses on cholestatic consequences.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Jorn C. Goet, Carla F. Murillo Perez, Maren H. Harms, Annarosa Floreani, Nora Cazzagon, Tony Bruns, Florian Prechter, George N. Dalekos, Xavier Verhelst, Nikolaos K. Gatselis, Keith D. Lindor, Willem J. Lammers, Aliya Gulamhusein, Anna Reig, Marco Carbone, Frederik Nevens, Gideon M. Hirschfield, Adriaan J. van der Meer, Henk R. van Buuren, Bettina E. Hansen, Albert Pares
Summary: This study evaluated the prognostic value of Mayo Risk Score (MRS), UK-PBC score, and GLOBE score in patients with primary biliary cholangitis, finding that the GLOBE score had superior discriminatory performance. However, all scores demonstrated comparable prediction accuracy for outcomes such as liver transplantation or death.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2021)
Review
Biochemistry & Molecular Biology
Annarosa Floreani, Daniela Gabbia, Sara De Martin
Summary: Ursodeoxycholic acid is the first-line therapy for PBC, but new pharmacological agents are being proposed for UDCA-non-responders. Obeticholic acid and fibrates have shown effectiveness in improving biochemistry alteration and symptoms of PBC. Other new agents with different mechanisms of action are also under clinical evaluation for PBC treatment.
Review
Gastroenterology & Hepatology
Juan Trivella, Binu V. John, Cynthia Levy
Summary: Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by destructive cholangitis and the presence of antimitochondrial antibodies. The prevalence of PBC varies globally and may be higher in males and racial minorities than previously thought. Early recognition and treatment are crucial for PBC outcomes, which can be influenced by provider bias and socioeconomic factors. Ursodeoxycholic acid is the initial treatment choice, with other drugs being considered as add-on therapy. This article provides a comprehensive summary of the epidemiology, prognosis, and treatment of PBC for holistic management.
HEPATOLOGY COMMUNICATIONS
(2023)
Article
Gastroenterology & Hepatology
Yanyun Shu, Yuhu Song, Tao Bai, Xiaoli Pan, Haitao Shang, Ling Yang, Jin Ye, Fan Du
Summary: The study identified total bilirubin, albumin, globulin, immunoglobin M, and aspartate aminotransferase-to-platelet ratio index as independent risk factors associated with early biochemical nonresponse to UDCA treatment. A predictor index was established based on these factors, with a predictive value of 0.886 (sensitivity: 82.80%, specificity: 84.40%). This predictor index is expected to provide valuable information for identifying high-risk patients before starting treatment.
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Ben Barron-Millar, Laura Ogle, George Mells, Steven Flack, Jonathan Badrock, Richard Sandford, John Kirby, Jeremy Palmer, Laura Jopson, John Brain, Graham R. Smith, Steve Rushton, Vinod S. Hegade, Rebecca Jones, Simon Rushbrook, Douglas Thorburn, Steve Ryder, Gideon Hirschfield, Jessica K. Dyson, David E. J. Jones
Summary: The UK-PBC study aimed to explore the biological basis of UDCA nonresponse in primary biliary cholangitis (PBC) and identified a set of serum chemokines potentially related to cellular senescence with significant differential expression between responders and nonresponders. These proteins have the potential to serve as biomarkers for high-risk disease identification and should be further evaluated for their clinical utility in prospective studies.
Article
Gastroenterology & Hepatology
Laura Martinez-Gili, Alexandros Pechlivanis, Julie A. K. McDonald, Sofina Begum, Jonathan Badrock, Jessica K. Dyson, Rebecca Jones, Gideon Hirschfield, Stephen D. Ryder, Richard Sandford, Simon Rushbrook, Douglas Thorburn, Simon D. Taylor-Robinson, Mary M. E. Crossey, Julian R. Marchesi, George Mells, Elaine Holmes, David Jones
Summary: A study on patients with primary biliary cholangitis (PBC) showed that there is variation in response to ursodeoxycholic acid (UDCA) treatment. Responders exhibited high levels of secondary and tertiary bile acids, while non-responders had lower urinary bile acid levels and higher levels of 12-dehydrocholic acid. Additionally, non-responders showed lower gut microbiota diversity and lower capacity for bile acid deconjugation.
Article
Immunology
Yi-jun Zhou, Gao-xiang Ying, Shi-lei Dong, Bo Xiang, Qiao-fei Jin
Summary: The gut microbiota of PBC patients from Zhejiang Province showed lower diversity and specific alterations compared to healthy controls. Six specific genera were identified as optimal biomarkers for the diagnosis of PBC. The changes in gut microbiota were associated with lipid metabolism and biosynthesis of secondary metabolites.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Annarosa Floreani, Daniela Gabbia, Sara De Martin
Summary: Primary biliary cholangitis (PBC) is a rare autoimmune liver disease with limited treatment options. Ursodeoxycholic acid (UDCA) is the first-line therapy but is ineffective for a significant portion of patients. Obeticholic acid (OCA) is an effective second-line treatment for UDCA-non responders. Future therapies for PBC are promising.
Review
Gastroenterology & Hepatology
Marlyn J. Mayo
Summary: The treatment for primary biliary cholangitis (PBC) with ursodeoxycholic acid (UDCA) may not be sufficient for all patients, and new approaches are needed. This review discusses potential therapeutic targets in PBC and provides examples of specific agents under development for the treatment of PBC, including targets related to bile, inflammation, cell survival, and fibrosis.
Review
Biochemistry & Molecular Biology
Ji-Won Park, Jung-Hee Kim, Sung-Eun Kim, Jang Han Jung, Myoung-Kuk Jang, Sang-Hoon Park, Myung-Seok Lee, Hyoung-Su Kim, Ki Tae Suk, Dong Joon Kim
Summary: Cholangiopathies are various biliary diseases that affect the biliary epithelium and can lead to cholestasis and liver cirrhosis. Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are the most important progressive cholangiopathies in adults, with research focusing on genetic risk, epigenetic changes, dysregulated mucosal immunity, and altered biliary epithelial cell function. Understanding the molecular pathogenesis of these diseases can help clinicians prevent and treat them more effectively.
Editorial Material
Gastroenterology & Hepatology
Malin Fromme, Henning W. Zimmermann, Tony Bruns
Article
Multidisciplinary Sciences
Moritz Kleinjans, Carolin Schneider, Tony Bruns, Pavel Strnad
Summary: Coeliac disease (CeD) shares similarities in morbidity and mortality with Crohn's disease (CD) and ulcerative colitis (UC), while the specific conditions of CeD may be driven by both inherited and acquired factors.
SCIENTIFIC REPORTS
(2022)
Article
Gastroenterology & Hepatology
Carla F. Murillo Perez, Alessio Gerussi, Palak J. Trivedi, Christophe Corpechot, Adriaan J. van der Meer, Pier Maria Battezzati, Keith D. Lindor, Frederik Nevens, Kris V. Kowdley, Tony Bruns, Nora Cazzagon, Annarosa Floreani, Atsushi Tanaka, Xiong Ma, Andrew L. Mason, Aliya Gulamhusein, Cyriel Y. Ponsioen, Marco Carbone, Ana Lleo, Marlyn J. Mayo, George N. Dalekos, Nikolaos K. Gatselis, Douglas Thorburn, Xavier Verhelst, Albert Pares, Harry L. A. Janssen, Gideon M. Hirschfield, Bettina E. Hansen, Pietro Invernizzi, Willem J. Lammers
Summary: This study investigates whether clinical outcomes of PBC patients in Western Europe differ according to geographical regions. The results show that patients from North Europe have higher biochemical markers and higher rates of poor outcomes (decompensation and liver transplantation) compared to those from South Europe.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Berivan Gurbuz, Nurdan Guldiken, Philipp Reuken, Lei Fu, Katharina Remih, Christian Preisinger, Radan Bruha, Martin Lenicek, Jaromir Petrtyl, Johanna Reissing, Mahmoud Aly, Malin Fromme, Biaohuan Zhou, Isabel Karkossa, Kristin Schubert, Martin von Bergen, Andreas Stallmach, Tony Bruns, Pavel Strnad
Summary: This study aimed to characterize changes in hepatocellular serum proteins and evaluate their diagnostic value in cirrhosis. Untargeted proteomic analysis of serum from 29 healthy controls and 43 patients with cirrhosis revealed 65 downregulated and 16 upregulated proteins in cirrhosis patients. Hierarchical clustering identified two main clusters and six sub-clusters. The study also found that serum apolipoprotein AI may be a useful prognostic marker in patients with decompensated cirrhosis.
HEPATOLOGY INTERNATIONAL
(2023)
Review
Gastroenterology & Hepatology
Marcus M. Muecke, Tony Bruns, Ali Canbay, Axel Matzdorff, Frank Tacke, Andreas Tiede, Jonel Trebicka, Heiner Wedemeyer, Kai Zacharowski, Stefan Zeuzem, Christian M. Lange
Summary: Advanced chronic liver disease often causes thrombocytopenia, requiring platelet transfusion before invasive procedures. However, platelet transfusions are associated with significant adverse events and high healthcare costs. Two well-tolerated drugs are now available for preemptive treatment of thrombocytopenia in patients with liver cirrhosis.
ZEITSCHRIFT FUR GASTROENTEROLOGIE
(2023)
Article
Gastroenterology & Hepatology
Emmanuel Weiss, Carlos de la Pena-Ramirez, Ferran Aguilar, Juan-Jose Lozano, Cristina Sanchez-Garrido, Patricia Sierra, Pedro Izquierdo-Bueno Martin, Juan Manuel Diaz, Francois Fenaille, Florence A. Castelli, Thierry Gustot, Wim Laleman, Agustin Albillos, Carlo Alessandria, Marco Domenicali, Paolo Caraceni, Salvatore Piano, Faouzi Saliba, Stefan Zeuzem, Alexander L. Gerbes, Julia A. Wendon, Christian Jansen, Wenyi Gu, Maria Papp, Raj Mookerjee, Carmine Gabriele Gambino, Cesar Jimenez, Ilaria Giovo, Giacomo Zaccherini, Manuela Merli, Antonella Putignano, Frank Erhard Uschner, Thomas Berg, Tony Bruns, Christian Trautwein, Alexander Zipprich, Rafael Banares, Jose Presa, Joan Genesca, Victor Vargas, Javier Fernandez, Mauro Bernardi, Paolo Angeli, Rajiv Jalan, Joan Claria, Christophe Junot, Richard Moreau, Jonel Trebicka, Vicente Arroyo
Summary: This study aimed to identify metabolites associated with short-term death in patients with acutely decompensated cirrhosis and design metabolomic prognostic models. Three prognostic metabolites strongly associated with death were selected and two models were built, which were found to be more accurate in predicting death within 7, 14, and 28 days compared to traditional scoring systems.
Article
Infectious Diseases
Jonathan F. Brozat, Miriam Haverkamp, Philipp Hohlstein, Jule K. Adams, Theresa H. Wirtz, Hanna R. Klingel, Susanne Huertgen, Karim Hamesch, Tony Bruns, Christian Trautwein, Samira Abu Jhaisha, Alexander Koch
Summary: Infectious diseases and the urgency to raise awareness about them become highly relevant due to global warming and multi-continent refugee crises. In this article, we present the challenges associated with malaria diagnosis, disease progression, and treatment, including a case of post-artesunate hemolysis in a severely ill Syrian refugee, most likely acquired during migrant smuggling from Turkey to Germany.
Article
Gastroenterology & Hepatology
Cristina Ripoll, Robin Greinert, Philipp Reuken, Matthias Christian Reichert, Susanne N. Weber, Yvonne Hupfer, Raphaela Staltner, Magdalena Meier Clinien, Frank Lammert, Tony Bruns, Alexander Zipprich
Summary: This study evaluates the association between the presence of NOD2 risk variants and BT, inflammation, and HE, and finds that NOD2 risk variants are not associated with HE, inflammation, BT, or immune activation. Instead, the presence of HE is linked to ammonia, the acute phase response, and myeloid cell activation.
LIVER INTERNATIONAL
(2023)
Review
Gastroenterology & Hepatology
Oliver Pabst, Mathias W. Hornef, Frank G. Schaap, Vuk Cerovic, Thomas Clavel, Tony Bruns
Summary: In this review, the gut-liver axis is discussed, focusing on the barriers formed by the enterohepatic tissues to restrict gut-derived microorganisms, microbial stimuli and dietary constituents. The establishment and regulation of structural and functional barriers, dynamics within the axis (immune responses and microbiome), and clinical implications are also highlighted.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
(2023)
Review
Gastroenterology & Hepatology
Oluwatomi Ibidapo-Obe, Tony Bruns
Summary: Chronic liver disease is caused by the coordinated response of innate and adaptive immunity components to liver tissue damage. The recruitment, positioning, and activation of immune cells can lead to hepatic cell death, inflammation, and fibrogenesis. The translocation of bacterial components from the intestine to other tissues contributes to persistent inflammation, immune dysfunction, and microbial infection.
Article
Gastroenterology & Hepatology
Marcus M. Muecke, Tony Bruns, Ali Canbay, Axel Matzdorff, Frank Tacke, Andreas Tiede, Jonel Trebicka, Heiner Wedemeyer, Kai Zacharowski, Stefan Zeuzem, Christian M. Lange
Summary: Advanced chronic liver disease often leads to changes in the coagulation system, requiring careful consideration of platelet transfusions before invasive procedures. Thrombopoetin-receptor agonists like Avatrombopaq and Lusutrombopaq are available to help manage thrombocytopenia in these patients, guiding clinicians on when to increase platelet counts appropriately.
ZEITSCHRIFT FUR GASTROENTEROLOGIE
(2023)
Meeting Abstract
Gastroenterology & Hepatology
Sophie Elisabeth Mueller, Cristina Ripoll, Alexander Zipprich, Tony Bruns, Paul Horn, Marcin Krawczyk, Frank Lammert, Matthias Reichert
JOURNAL OF HEPATOLOGY
(2022)
Meeting Abstract
Gastroenterology & Hepatology
Jonathan Frederik Brozat, Frank Hanses, Martina Haselberger, Melanie Stecher, Michael Dreher, Lukas Tometten, Maria Madeleine Ruethrich, Janne Vehreschild, Christian Trautwein, Stefan Borgmann, Maria Vehreschild, Carolin E. M. Jakob, Andreas Stallmach, Kai Wille, Kerstin Hellwig, Nora Isberner, Philipp Reuken, Fabian Geisler, Jacob Nattermann, Tony Bruns
JOURNAL OF HEPATOLOGY
(2022)
Meeting Abstract
Gastroenterology & Hepatology
Benedikt Csernalabics, Stefan Marinescu, Lars Maurer, Katharina Wild, Katharina Zoldan, Marcus Panning, Philipp Reuken, Tony Bruns, Christoph Neumann-Haefelin, Bertram Bengsch, Maike Hofmann, Robert Thimme, Viet Loan Dao Thi, Tobias Boettler
JOURNAL OF HEPATOLOGY
(2022)